Azitra, Inc. - 8-K Filing

Azitra announces ATR-COSF ex vivo results showing 56% wrinkle reduction and expands ATR-04 Phase 1/2 trial scope (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits (d) Exhibits)

SEC EDGAR ·

Tickers: $AZTR

Read the full article at SEC EDGAR

More Regulatory news